| Travis Lee Tyler, MS, PT | |
|
168 Pucky Huddle Rd, Bethel, NY 12720-5207 | |
| (914) 799-1861 | |
| Not Available |
| Full Name | Travis Lee Tyler |
|---|---|
| Gender | Male |
| Speciality | Physical Therapist |
| Location | 168 Pucky Huddle Rd, Bethel, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023089786 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 025111-1 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Travis Lee Tyler, MS, PT 168 Pucky Huddle Rd, Bethel, NY 12720-5207 Ph: (914) 799-1861 | Travis Lee Tyler, MS, PT 168 Pucky Huddle Rd, Bethel, NY 12720-5207 Ph: (914) 799-1861 |
News Archive
Merit Medical Systems, Inc., a leading manufacturer and marketer of proprietary disposable medical devices used in interventional and diagnostic procedures, particularly in cardiology, radiology and gastroenterology, today announced record revenues of $74.9 million for the quarter ended June 30, 2010, an increase of 16% over revenues of $64.8 million for the quarter ended June 30, 2009. Revenues for the six-month period ended June 30, 2010 were a record $142.4 million, compared with $123.2 million for the corresponding period in 2009, a gain of 16%.
Actinium Pharmaceuticals, Inc. a biotechnology company focused on developing innovative, alpha particle radiotherapy targeted cancer treatments addressing major unmet medical needs, today announced that it has successfully treated the first cohort of patients in a Phase I/II study of Actimab-A in Acute Myeloid Leukemia (AML) clinical trial. Patients were treated at Memorial Sloan Kettering Cancer Center in New York City.
Epiphany Biosciences announced results from its Phase 2b dose-ranging study of EPB-348 (valomaciclovir) in patients with shingles (herpes zoster) infection. The study's primary endpoint was non-inferiority of once-daily valomaciclovir compared to thrice-daily valacyclovir in terms of time to complete crusting of the shingles rash.
Results from a phase III trial have shown that tecemotide is no more effective than placebo as maintenance therapy in patients with non-small-cell lung cancer.
› Verified 2 days ago
Hudson Valley Rehab Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 168 Pucky Huddle Rd, Bethel, NY 12720 Phone: 845-807-7462 |